Nanoparticle-mediated drug delivery and pulmonary hypertension

Hypertension

Volumn 53, Issue 5, 2009, Pages 751-753

  Bonner, James C ^a   Card, Jeffrey W ^b   Zeldin, Darryl C ^c  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b Cantox Health Sciences International   (Canada)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NANOPARTICLE; OLIGODEOXYNUCLEOTIDE;

DRUG DELIVERY SYSTEM; NANOPHARMACEUTICS; NANOTECHNOLOGY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN TARGETING; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION;

ANIMALS; DRUG DELIVERY SYSTEMS; HYPERTENSION, PULMONARY; NANOPARTICLES; NANOTUBES, CARBON; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; RATS;

EID: 73549084986     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.122846     Document Type: Note

References (10)

1. 1. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3:133-149. (Pubitemid 352042401)
2. Kimura S, Egashira K, Chen L, Nakano K, Iwata E, Miyagawa M, Tsujimoto H, Hara K, Morishita R, Sueishi K, Tominaga R, Sunagawa K. Nanoparticle-mediated delivery of nuclear factor KB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension. 2009;53:877-883.
3. Perkins ND. Integrating cell-signalling pathways with NF-kB and IKK function. Nature Rev Mol Cell Biol. 2007;8:49-62.
4. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res. 1998;82:1023-1028.
5. 5. Sawada H, Mitani Y, Maruyama J, Jiang BH, Ikeyama Y, Dida FA, Yamamoto H, Imanaka-Yoshida K, Shimpo H, Mizoguchi A, Maruyama K, Komada Y. A nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest. 2007;132: 1265-1274. (Pubitemid 47621003)
6. 6. Gilmore TD, Herscovitch M. Inhibitors of NF-kB signaling: 785 and counting. Oncogene. 2006;25:6887-6899. (Pubitemid 44657858)
7. Card JW, Zeldin DC, Bonner JC, Nestmann ER. Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol. 2008 ;295:L400-L411.
8. Prato M, Kostarelos K, Bianco A. Functionalized carbon nanotubes in drug design and discovery. Ace Chem Res. 2008;41:60-68.
9. Ryman-Rasmussen JP, Tewksbury EW, Moss OR, Cesta MF, Wong BA, Bonner JC. Inhaled multiwalled carbon nanotubes potentiate airway fibrosis in a murine model of allergic asthma. Am J Resp Cell Mol Biol. 2009;40:349-358.
10. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2007;2:469-478.